Zoono Group (ASX:ZNO) is no longer just asking investors to think about antimicrobial sprays, wipes and surface protection. The company is trying to make food packaging the main event.
That is a cleaner story than the one Zoono carried through the post-pandemic years. It is also a harder one to prove. Food packaging is a bigger, more repeatable market if the product works at commercial scale, but the market will probably care less about trial counts and more about repeat orders, cash receipts and contract conversion.
The latest quarterly update gave investors something more useful than a slogan. Zoono said cash receipts increased by NZ$333,000 due to orders from new packaging manufacturing partners, and disclosed initial orders of about NZ$585,000 under existing contracts with food packaging manufacturers. The company also said further orders were expected in the current quarter, along with cash receipts from sales made in the quarter ended 31 March 2026.
The old Zoono story is being replaced
Zoono still describes itself as a global biotech company that develops and distributes long-lasting antimicrobial solutions, including products for skin care, surface sanitisers and mould remediation. Its own description of the technology is built around the “Zoono molecule”, which bonds to surfaces and targets pathogens including bacteria, viruses, algae, fungi and mould.
The newer investor pitch is narrower and more interesting. Zoono’s investor centre says the company is repositioning toward B2B markets, especially antimicrobial technology applied to food packaging for shelf-life extension and food waste reduction. It points to three commercial deals with packaging manufacturers, Sharpak/Guillin in the UK, Mpact in South Africa and Multisteps in Australia, with minimum annual purchases totalling NZ$50 million over five years.
That is the turn in the story. Zoono is trying to move from consumer-facing germ protection into a packaging channel where the product sits inside a customer’s operating system. If that happens, the business becomes less about brand awareness and more about industrial adoption.
The catch is simple. Packaging contracts only matter if they become recurring sales.
The first receipts matter because the base is still small
The March-quarter Appendix 4C showed customer receipts of NZ$500,000 for the quarter and NZ$908,000 for the nine months to 31 March 2026. Net operating cash outflow was NZ$183,000 for the quarter and NZ$1.574 million for the nine-month period.
That mix tells the story better than a long spreadsheet would. The receipts are starting to appear, but the company is still working from a small revenue base and still using cash at the operating level.
Zoono’s FY25 result also shows why the pivot matters. Revenue from ordinary activities rose 19.1% to NZ$1.25 million, while the loss attributable to owners narrowed 59.0% to NZ$3.77 million. That is improvement, but it is not yet the profile of a company that has proved commercial scale.
The question is whether the packaging channel can change that profile quickly enough.
The OSY link gives the strategy a sharper edge
One reason the packaging push deserves attention is the OSY connection. In August 2025, Zoono raised a further A$992,000 through a shortfall placement, bringing the rights-offer total to A$1.78 million, or NZ$1.95 million, before costs. The placement was made to investors associated with OSY Group, which Zoono described as a key driver of the shelf-life extension project.
The same announcement included performance-linked incentives for Marc Braterman, CEO of OSY Group. Zoono agreed to issue up to 5 million free shares subject to sales hurdles in the shelf-life extension food packaging channel, starting with NZ$5 million in gross sales by 31 December 2026, then higher targets tied to 2027 and 2028.
That is a useful detail. It puts dates and numbers around the commercial ambition. It also gives investors a clearer way to judge the rollout.
The share structure is still part of the story
Zoono also has capital-structure noise to manage. On 18 May 2026, the company advised that 7,201,598 unlisted options exercisable at A$0.10 would expire on 2 June 2026. The company said Zoono shares last traded at A$0.068 before that notice, with a three-month high of A$0.078 and low of A$0.054.
For a small-cap stock, that matters. The market is not only weighing the shelf-life extension opportunity. It is also weighing funding history, option overhangs, liquidity and the gap between early commercial orders and larger contracted revenue.
The stronger reading is that Zoono has a more focused commercial path than it had a year ago. The more cautious reading is that the company still needs to convert a promising channel into sustained cash receipts.
The next quarter has to do more than repeat the pitch
The next useful signal is not another broad market-size statement. It is whether the NZ$585,000 of initial orders becomes part of a larger pattern, whether further orders arrive as flagged, and whether operating cash outflow keeps narrowing as receipts improve.
Zoono’s story has become easier to understand. The company is trying to become a food shelf-life extension play, not simply a legacy antimicrobial-products name. That gives the market something cleaner to watch.
